Micropace Pty Ltd is an Australian-based medical technology company specialising in the design, development, and global distribution of advanced cardiac electrophysiology (EP) diagnostic and stimulation systems. Headquartered in Sydney, Micropace has established itself as a recognised innovator in the field of cardiac rhythm management, with a primary focus on delivering high-performance, reliable, and clinically precise solutions that support electrophysiologists in diagnosing and treating complex cardiac arrhythmias.

Founded with a vision to improve patient outcomes through technological excellence, Micropace has developed a strong reputation for engineering quality, clinical usability, and regulatory compliance. The company’s flagship product line, including the EPS320 Cardiac Stimulator and its associated components and accessories, is widely adopted in EP laboratories for intracardiac stimulation, pacing, and diagnostic testing. These systems are designed to meet the demanding requirements of modern electrophysiology procedures, offering precise timing control, intuitive user interfaces, and seamless integration into clinical workflows.

Micropace’s value proposition is centred on delivering clinically relevant innovation. The company works closely with leading electrophysiologists and healthcare institutions to ensure that its products address real-world procedural needs. This collaborative approach has enabled Micropace to continuously refine its technology, incorporating user feedback into product enhancements and maintaining alignment with evolving clinical standards. The result is a portfolio of solutions that are not only technically robust but also highly practical in busy clinical environments.

Quality and regulatory compliance are core pillars of Micropace’s operations. The company adheres to stringent international standards, including ISO 13485 for medical device quality management systems, and its products are approved or registered with key regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Union under CE marking (MDR), the Therapeutic Goods Administration (TGA) in Australia, and other relevant agencies globally. This commitment ensures that Micropace devices meet the highest levels of safety, performance, and reliability required in critical cardiac procedures.

In addition to its core hardware systems, Micropace provides a comprehensive ecosystem of accessories and support solutions, including specialised EP catheters interfaces, cables, and software features that enhance procedural efficiency. The company also invests in ongoing technical support, training, and customer service to ensure optimal product utilisation and long-term client satisfaction. This end-to-end approach reinforces Micropace’s position as not just a device manufacturer, but a trusted partner to healthcare providers.

From a market perspective, Micropace has successfully expanded its footprint across multiple international regions, supported by a network of distributors, authorised representatives, and strategic partners. The company serves a diverse range of markets, including:

• North America: The United States represents a key market, where Micropace products are used in leading hospitals and cardiac centres. Regulatory clearance through the FDA has enabled strong adoption in a highly competitive and innovation-driven environment.
• Europe: Micropace has a well-established presence across the European Union and the United Kingdom, supported by CE marking under the Medical Device Regulation (MDR). The company works with experienced distributors to navigate diverse healthcare systems and procurement frameworks across the region.
• Asia-Pacific (APAC): As an Australian company, Micropace maintains a strong presence in the APAC region, including Australia, New Zealand, China, Hong Kong, Taiwan, South Korea, and Southeast Asian countries such as Singapore, Malaysia, Thailand, and Vietnam. These markets are strategically important due to their growing healthcare infrastructure and increasing demand for advanced cardiac care.
• Middle East: Micropace serves selected markets in the Middle East, where there is significant investment in healthcare modernisation and specialised cardiac services. The company collaborates with regional distributors to support market access and regulatory compliance.
• Latin America: Emerging markets in Latin America represent growth opportunities for Micropace, with distribution channels supporting access to countries such as Brazil, Mexico, and others where cardiac disease management is a priority.
• Other Global Markets: Micropace continues to evaluate and expand into additional territories through partnerships and regulatory approvals, ensuring broader access to its technology worldwide.

Micropace’s international strategy is underpinned by a flexible and scalable distribution model. By partnering with established local distributors and authorised representatives, the company is able to navigate complex regulatory environments, provide localised support, and ensure timely market access. This model also allows Micropace to remain agile and responsive to regional market dynamics while maintaining central oversight of quality and brand integrity.

Innovation remains a central focus for Micropace as it looks to the future. The company continues to invest in research and development to enhance its product offerings, with an emphasis on improving procedural efficiency, data integration, and user experience. As electrophysiology continues to evolve with advancements in mapping technologies, ablation techniques, and digital health integration, Micropace is well positioned to contribute to the next generation of cardiac diagnostic and therapeutic tools.

In summary, Micropace Pty Ltd is a globally active, Australian medical device company with a strong reputation in the field of cardiac electrophysiology. Through its commitment to innovation, quality, and customer collaboration, the company delivers specialised solutions that support clinicians in improving patient outcomes. With an expanding international presence across North America, Europe, Asia-Pacific, the Middle East, and Latin America, Micropace continues to strengthen its position as a trusted provider of advanced cardiac stimulation technologies in the global healthcare market.

Why work with us

1. Clinically Proven, Specialist Technology

Micropace is highly specialised in cardiac electrophysiology (EP). Its core systems, such as the EPS320 Cardiac Stimulator, are purpose-built for EP labs and widely regarded for precision, reliability, and ease of use. This clinical focus allows distributors to represent a product with strong credibility among electrophysiologists, rather than competing on commoditised or lower-differentiation devices.

2. Strong Reputation with Key Opinion Leaders (KOLs)

Micropace has built long-standing relationships with leading electrophysiologists globally. This translates into real clinical endorsement, smoother product adoption, and reduced resistance during market entry. For distributors, this significantly shortens sales cycles and strengthens positioning in competitive tenders.

3. Premium Quality with Competitive Pricing

Micropace offers a compelling balance between high-end performance and cost-effectiveness. Compared to larger multinational competitors, Micropace systems often deliver equivalent clinical functionality at a more attractive price point. This creates a clear value proposition for hospitals and provides distributors with stronger margin flexibility and competitive leverage.

4. Streamlined Product Portfolio (Focused and Sellable)

Unlike broad portfolios that dilute focus, Micropace’s offering is targeted and coherent. This makes it easier for distributors to train their sales teams, position the product, and build expertise quickly. A focused portfolio also reduces inventory complexity and operational burden.

5. Regulatory Strength and Market Access Support

Micropace products are approved in major regulated markets, including FDA (USA), CE Mark under MDR (Europe), and TGA (Australia). This reduces regulatory risk for distributors and accelerates time-to-market. In addition, Micropace actively supports partners with technical documentation, compliance guidance.

6. Distributor-Centric Partnership Model

Micropace operates with a partnership mindset rather than a transactional sales approach. Distributors benefit from:

• Responsive and direct communication with decision-makers
• Flexibility in commercial arrangements
• Willingness to support local market strategies
• Long-term relationship focus rather than short-term volume targets

7. Strong Technical and Clinical Support

Micropace provides comprehensive onboarding, product training, and ongoing technical support. This ensures distributors can confidently support installations, clinical use, and troubleshooting. The availability of expert-level support reduces post-sale risk and enhances customer satisfaction.

8. Ease of Integration into Clinical Workflow

Micropace systems are designed with usability in mind, allowing seamless integration into existing EP lab environments. This reduces barriers to adoption and minimises the need for extensive retraining or workflow disruption—key factors that influence purchasing decisions.

9. Reliable Supply and Operational Agility

As a focused and agile organisation, Micropace is often able to respond more quickly to distributor needs compared to large multinational competitors with complex supply chains. This includes responsiveness on orders, customisation requests, and issue resolution—critical factors in maintaining customer trust.

10. Growth Potential in an Expanding Market

Cardiac electrophysiology is a growing global segment driven by increasing incidence of arrhythmias and ageing populations. By partnering with Micropace, distributors gain access to a niche but expanding market with strong clinical demand and repeat business potential (systems, accessories, and replacements).